ADVERTISEMENT
Novel Research on Aortic Stenosis From egnite, Inc.’s Database Presented at Transcatheter Cardiovascular Therapeutics Conference 2023
Key Findings Demonstrate Patients With Aortic Stenosis Have Substantial Untreated Mortality Risk Across All Levels of Aortic Stenosis Severity, but Aortic Valve Replacement Rates Remain Low Even for Patients With Severe Aortic Stenosis
Key Findings Demonstrate Patients With Aortic Stenosis Have Substantial Untreated Mortality Risk Across All Levels of Aortic Stenosis Severity, but Aortic Valve Replacement Rates Remain Low Even for Patients With Severe Aortic Stenosis
ALISO VIEJO, Calif.--egnite, Inc., a leading cardiovascular digital health company, announced that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
This study, simultaneously published in the Journal of the American College of Cardiology (JACC), leveraged egnite’s de-identified real-world database of over one million patients across 24 teaching and non-teaching United States health systems. Généreux and colleagues sought to unveil treatment patterns and outcomes associated with AS over 4 years.
Key findings demonstrated:
- Patients with AS have substantial untreated mortality risk across all levels of AS severity, but rates of treatment with aortic valve replacement (AVR) remain low (even for patients with severe AS, ~60% were treated within 4 years);
- Moderate AS was almost as deadly as severe AS at 4 years without AVR.
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients with moderate AS may benefit from intervention,” says Généreux.
This study builds upon a robust body of medical research on the outcomes of patients with AS, highlighting the need for early identification and timely treatment of disease.
About egnite, Inc.
egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.
egnite, egnite, Inc., and the spark logo are trademarks of egnite, Inc. All other trademarks are the property of their respective owners.
Keep reading:
